«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

[1]肖瑜,龙驰,张明慧,等.Beclin-1在非小细胞肺癌中的表达与意义[J].第三军医大学学报,2013,35(12):1271-1273.

点击复

Xiao Yu,Long Chi,Zhang Minghui,et al.Expression of Beclin-1 in non-small cell lung cancer and its clinical significance[J]. J Third Mil Med Univ,2013,35(12):1271-1273.



Beclin-1在非小细胞肺癌中的表达与意义(PDF) 分享到。

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R] 卷: 35 期数: 2013年第12 期 页码: 1271-1273 栏目: 论著 出版日期: 2013-06-30

Title: Expression of Beclin-1 in non-small cell lung cancer and

its clinical significance

作者: 肖瑜; 龙驰; 张明慧; 罗焱; 胡义德

第三军医大学新桥医院全军肿瘤诊治研究所

Author(s): Xiao Yu; Long Chi; Zhang Minghui; Luo Yan; Hu Yide

Institute of Ocancer, Diagnosis and Treatment, Xingiao Hospital,

Third Military Medical University, Chongqing, 400037, China

关键词: 非小细胞肺癌; 自噬; Beclin-1; 组织芯片

Keywords: NSCLC; autophagy; Beclin-1; tissue chip

分类号: R446.9, R730.23, R734.2

文献标志码: A

摘要:

探讨自噬重要调控因子Beclin-1在非小细胞肺癌 (non-small 目的 cell lung cancer, NSCLC) 中的表达及其临床意义。 收集 150例非小细胞肺癌患者的癌组织及癌旁组织并制成组织芯片,应用免 疫组化的方法检测Beclin-1在肺癌组织及癌旁组织中的表达情况。分析 Beclin-1的表达与肺癌不同临床参数之间的关系并对病例进行生存分 析。 Beclin-1在肺癌组织的阳性表达率 (26.00%) 显著低 结果 于癌旁组织(82.00%)(P<0.05);肺鳞癌组织中Beclin-1的阳性表达 率 (34.66%) 显著高于肺腺癌(17.34%) (P<0.05); Beclin-1的表达率在 不同性别、年龄、分化程度、淋巴结转移、远处转移组间无显著差异 (P>0.05) , Beclin-1阴性表达的非小细胞肺癌患者的生存率显著低于 阳性表达的患者 (P<0.05)。 结论 Beclin-1可能是一个非小细 胞肺癌治疗的新的靶点,有可能成为非小细胞肺癌病理类型判断的辅助

Abstract: Objective To investigate the expression level of an important

指标和预后评估候选指标之一。

autophagy-related factor Beclin-1 in non-small cell lung cancer (NSCLC) and its clinical significance. Methods The

specimens of carcinoma tissues and their paired para-carcinoma tissues collected from 150 NSCLC patients were made into tissue

microarray. Immunohistochemistry (IHC) was applied to detect the

导航/NAVIGATE

本期目录/Table of Contents

下一篇/Next Article

上一篇/Previous Article

工具/TOOLS

引用本文的文章/References

下载 PDF/Download PDF(740KB)

立即打印本文/Print Now

查看/发表评论/Comments

导出

统计/STATISTICS

摘要浏览/Viewed 195

全文下载/Downloads 106

评论/Comments

RSS XML

expression level of Beclin-1 in these specimens. The correlation between the expression level of Beclin-1 and the survive rate of patients with NSCLC was analyzed. Results The positive expression rate of Beclin-1 in the carcinoma tissues (26.00%) was significantly lower than that in the para-carcinoma tissues (82.00%) (P<0.05), and the positive expression rate of Beclin-1 in squamous cell carcinoma tissues (34.66%) was significantly higher than that in the adenocarcinoma tissues (17.34%) (P<0.05). However, no evidence showed the expression rate of Beclin-1 was correlated with sex, age, degrees of differentiation, lymph node metastasis and distant metastasis (P>0.05). The survive rate of the NSCLC patients with negative expression of Beclin-1 was significantly lower than that of the NSCLC patients with positive expression of Beclin-1 (P<0.05). Conclusion Beclin-1 may be used as a new target for NSCLC treatment and as a potential indicator for pathological diagnosis and prognostic prediction of NSCLC.

参考文献/REFERENCES:

肖瑜, 龙驰, 张明慧, 等. Beclin-1在非小细胞肺癌中的表达与意义[J].第三军医大学学报,2013,35(12):1271-1273. 相似文献/REFERENCES:

[1]丁雯,倪振洪,程攀科,等.左旋棉酚通过细胞自噬下调Namalwa细胞中B淋巴细胞刺激因子的表达[J].第三军医大学学报,2012,34(16):1613.

Ding Wen, Ni Zhenhong, Cheng Panke, et al. Mechanism of (-)-gossypol down-regulating B lymphocyte stimulator expression in Namalwa cells via autophagy[J]. J Third Mil Med Univ, 2012, 34(12):1613.

[2] 蒋娟, 易亭伍, 张瑜, 等. 非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J]. 第三军医大学学报, 2012, 34(20): 2039.

Jiang Juan, Yi Tingwu, Zhang Yu, et al. Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J]. J Third Mil Med Univ, 2012, 34(12): 2039.

[3]张岩巍,刘友如,张雪艳,等.107例经EGFR-TKIs一线治疗的非小细胞肺癌患者血肿瘤标记物水平与疗效的关系[J].第三军医大学学报,2012,34(20):2051.

Zhang Yanwei, Liu Youru, Zhang Xueyan, et al. Relationship between tumor marker levels and efficacy of EGFR-TKIs first-line treatment in non-small cell lung cancer patients[J]. J Third Mil Med Univ, 2012, 34 (12):2051.

[4]刘璐,王永生,何雅億,等.晚期非小细胞肺癌患者血清细胞因子IL-18、IL-2R、IL-6及TNF-α水平与厄洛替尼疗效的相关性研究[J].第三军医大学学报,2012,34(20):2056.

Liu Lu, Wang Yongsheng, He Yayi, et al. Correlation of serum cytokine levels with erlotinib treatment outcome in patients with advanced non-small cell lung cancer[J]. J Third Mil Med Univ, 2012, 34(12):2056. [5]杨庆羚, 刘翩, 王斌, 等. EGFR-TKIs治疗晚期非小细胞肺癌并发间质性肺炎4例报告并文献复习[J]. 第三军医大学学报, 2012, 34(20):2060.

Yang Qingling, Liu Pian, Wang Bin, et al. Interstitial pneumonia in EGFR-TKIs-treated non-small-cell lung